Defects within the nanoscale UiO-66 metal-organic framework (MOF) are created to lock a hybrid phosphonoacetate ligand through Zr-O-P linkages, leaving the carboxyl group free to anchor cisplatin prodrug cis, cis,… Click to show full abstract
Defects within the nanoscale UiO-66 metal-organic framework (MOF) are created to lock a hybrid phosphonoacetate ligand through Zr-O-P linkages, leaving the carboxyl group free to anchor cisplatin prodrug cis, cis, trans-[Pt(NH3)2Cl2(OH)2]. A drug loading of 256.5 mg g-1 (25.7 wt% based on cisplatin) was achieved with a Zr6 : Pt : P ratio of 1.5 : 1 : 1, which surpasses defect-free UiO-66 and several other MOF carriers. This framework exhibited a burst release of its payload in PBS solution in the first 2 h, releasing 71% of the drug, including a 50% payload release in less than 1 h. This work demonstrates that MOF defects can be intentionally engineered to achieve a high drug loading, and serves as an alternative to drug encapsulation using the pore void and through the association of the functionalized ligand.
               
Click one of the above tabs to view related content.